Table 1.
Basic information of the included articles.
| Study | Year | Country | Design | Cancer type | Sample size | Analysis type | Survival analysis | Treatment methods | NOS score |
|---|---|---|---|---|---|---|---|---|---|
| Hannarici | 2023 | Turkey | R | Gastric cancer | 159 | Multivariate analysis | OS,PFS | Non-surgery | 7 |
| Navarro | 2019 | Korea | R | Gallbladder Cancer | 197 | Multivariate analysis | OS,DFS | Surgery | 7 |
| Ni | 2022 | China | R | Renal cancer | 420 | Multivariate analysis | OS | Surgery | 7 |
| Song | 2022 | China | R | Lung cancer | 1772 | Multivariate analysis | OS | Non-surgery | 8 |
| Yang | 2022 | China | R | Lung cancer | 862 | Multivariate analysis | OS | Surgery | 7 |
| Yang | 2022 | China | R | Colorectal cancer | 1448 | Multivariate analysis | OS | Surgery | 7 |
| Yilmaz | 2021 | China | R | Liver cancer | 150 | Multivariate analysis | OS,PFS | Non-surgery | 7 |
| Yilmaz | 2022 | China | R | Breast cancer | 110 | Multivariate analysis | OS,PFS | Non-surgery | 7 |
| Zhang | 2021A | China | R | Pancreatic cancer | 130 | Multivariate analysis | OS | Surgery | 6 |
| Zhang | 2021B | China | R | Pancreatic cancer | 129 | Multivariate analysis | OS | Surgery | 6 |
| Zhong | 2020 | China | R | Pancreatic cancer | 238 | Multivariate analysis | OS | Non-surgery | 6 |
| Liu | 2024A | China | R | Lung cancer | 240 | Multivariate analysis | OS | Surgery | 6 |
| Liu | 2024B | China | R | Colorectal cancer | 378 | Multivariate analysis | OS | Surgery | 6 |
| Liu | 2024C | China | R | Breast cancer | 221 | Multivariate analysis | OS | Surgery | 6 |
| Liu | 2024D | China | R | Gastric cancer | 335 | Multivariate analysis | OS | Surgery | 6 |
| Liu | 2024E | China | R | Liver cancer | 270 | Multivariate analysis | OS | Surgery | 6 |
| Liu | 2024F | China | R | Esophageal Cancer | 233 | Multivariate analysis | OS | Surgery | 6 |
| Liu | 2024H | China | R | Renal Cancer | 295 | Multivariate analysis | OS | Surgery | 6 |
| Liu | 2024G | China | R | Melanoma | 200 | Multivariate analysis | OS | Surgery | 6 |
| Zhang | 2023 | China | R | Breast cancer | 1125 | Multivariate analysis | OS | Non-surgery | 8 |
| Aydin | 2024 | Turkey | R | Colorectal cancer | 222 | Multivariate analysis | OS | Surgery | 6 |
| Park | 2024 | Korea | R | Pancreatic cancer | 338 | Multivariate analysis | OS | Surgery | 6 |
R, retrospective; OS, overall survival; DFS, disease-free survival; PFS, progression-free survival; NOS score, Newcastle-Ottawa Scale score.